NASDAQ:CELZ - Nasdaq - US22529Y4089 - Common Stock - Currency: USD
NASDAQ:CELZ (5/22/2025, 1:16:23 PM)
1.95
-0.03 (-1.52%)
The current stock price of CELZ is 1.95 USD. In the past month the price increased by 0.51%. In the past year, price decreased by -54.06%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.75 | 322.47B | ||
AMGN | AMGEN INC | 13.05 | 145.63B | ||
GILD | GILEAD SCIENCES INC | 13.78 | 132.82B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.12B | ||
REGN | REGENERON PHARMACEUTICALS | 13.46 | 64.39B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.70B | ||
ARGX | ARGENX SE - ADR | 98.89 | 35.45B | ||
ONC | BEIGENE LTD-ADR | 5.92 | 25.67B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.71B | ||
NTRA | NATERA INC | N/A | 20.85B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.28B | ||
BIIB | BIOGEN INC | 7.98 | 18.50B |
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company which focuses on immunology, urology, neurology and orthopedics using adult stem cell treatments and interrelated regenerative technologies for the treatment of multiple indications. The company is headquartered in Phoenix, Arizona and currently employs 4 full-time employees. The company went IPO on 2009-05-01. The firm conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.
CREATIVE MEDICAL TECHNOLOGY
211 E. Osborn Rd.
Phoenix ARIZONA US
Employees: 4
Phone: 14803992822
The current stock price of CELZ is 1.95 USD. The price decreased by -1.52% in the last trading session.
The exchange symbol of CREATIVE MEDICAL TECHNOLOGY is CELZ and it is listed on the Nasdaq exchange.
CELZ stock is listed on the Nasdaq exchange.
7 analysts have analysed CELZ and the average price target is 26.52 USD. This implies a price increase of 1260% is expected in the next year compared to the current price of 1.95. Check the CREATIVE MEDICAL TECHNOLOGY stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CREATIVE MEDICAL TECHNOLOGY (CELZ) has a market capitalization of 5.05M USD. This makes CELZ a Nano Cap stock.
CREATIVE MEDICAL TECHNOLOGY (CELZ) currently has 4 employees.
CREATIVE MEDICAL TECHNOLOGY (CELZ) has a support level at 1.96 and a resistance level at 2.08. Check the full technical report for a detailed analysis of CELZ support and resistance levels.
The Revenue of CREATIVE MEDICAL TECHNOLOGY (CELZ) is expected to decline by -100% in the next year. Check the estimates tab for more information on the CELZ EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CELZ does not pay a dividend.
CREATIVE MEDICAL TECHNOLOGY (CELZ) will report earnings on 2025-08-07.
CREATIVE MEDICAL TECHNOLOGY (CELZ) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.81).
The outstanding short interest for CREATIVE MEDICAL TECHNOLOGY (CELZ) is 1.76% of its float. Check the ownership tab for more information on the CELZ short interest.
ChartMill assigns a technical rating of 1 / 10 to CELZ. When comparing the yearly performance of all stocks, CELZ is a bad performer in the overall market: 96.25% of all stocks are doing better.
ChartMill assigns a fundamental rating of 4 / 10 to CELZ. No worries on liquidiy or solvency for CELZ as it has an excellent financial health rating, but there are worries on the profitability.
Over the last trailing twelve months CELZ reported a non-GAAP Earnings per Share(EPS) of -3.81. The EPS decreased by -2.42% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -82.37% | ||
ROE | -86.63% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to CELZ. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 44.19% and a revenue growth -100% for CELZ